Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,157
Out of 5,165 analysts
31
Total ratings
35.29%
Success rate
-24.26%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $26.55 | +58.19% | 1 | Nov 5, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $534.30 | -19.15% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $4.53 | +76.60% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $56 → $12 | $9.15 | +31.15% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $71.03 | -53.54% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.25 | +2,140.00% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $27.39 | -1.42% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.86 | +276.34% | 1 | Feb 10, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.67 | +581.20% | 1 | Nov 14, 2022 | |
| NCNA NuCana | Maintains: Buy | $105,000 → $15,000 | $1.90 | +789,373.68% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.67 | +1,397.01% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $28.29 | +23.72% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $366.25 | -39.93% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $183.26 | +69.16% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $145.21 | -44.91% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $26.55
Upside: +58.19%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $534.30
Upside: -19.15%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $4.53
Upside: +76.60%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $56 → $12
Current: $9.15
Upside: +31.15%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $71.03
Upside: -53.54%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.25
Upside: +2,140.00%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $27.39
Upside: -1.42%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.86
Upside: +276.34%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.67
Upside: +581.20%
NuCana
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $1.90
Upside: +789,373.68%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.67
Upside: +1,397.01%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $28.29
Upside: +23.72%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $366.25
Upside: -39.93%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $183.26
Upside: +69.16%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $145.21
Upside: -44.91%